On Wednesday, December 4, Lincoln Pharmaceuticals experienced a 20 per cent rise in intraday trading on the BSE, reaching its upper circuit and a record high of ₹904.90. The price of Lincoln Pharma’s shares soared 20% to reach an all-time high, opening at ₹782.90 from its previous closing of ₹754.10. Just three sessions in December saw a 38% increase in the small-cap stock.
As stated in its exchange registration, Lincoln Pharma has no debt. It had a healthy return ratio as of September 2024, with investments totalling over ₹164 crores and a net profit of over ₹100 crores annually.
In comparison to the net profit of ₹46.52 crore in H1FY24, the company’s standalone net profit for the half-year ending September 30, 2024, was ₹50.03 crore, representing a 7.55% YoY improvement.
Operational revenue for the H1FY25 was ₹308.50 crore, representing a 5.79rcentts YoY increase. EBITDA increased 4.76 per cent year over year to ₹71.50 crore during the period.
Commenting on the H1FY25 results and performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said, “We are pleased to report continued strong growth across all business verticals in H1FY25 (first half of financial year 2025) while maintaining a net debt-free status. Our new product launches in domestic and export markets have strengthened our market presence and accelerated growth, positioning us for even better performance during the second half of the year.”
“Through a combination of robust growth initiatives, high-quality products, geographic expansion, and operational improvements, we are on track to achieve our ambitious ₹750 crore revenue target by FY26. We are among a select group of companies that have consistently achieved profit growth every year from FY3 to FY24,” Patel said.
The business exports to more than 60 nations globally. It claimed that it is ready for more international growth given its recent entry into the Canadian market and the approvals it received from TGA—Australia and EU GMP. Additionally, it is actively seeking product registration for its Mehsana-based Cephalosporin plant. These efforts are in line with the company’s FY26 sales goal of ₹750 crore.
Today, December 4, Lincoln Pharma’s stock reached a record high of ₹904.90. From its 52-week low of ₹498 on June 5 of this year, they have risen 82% to this price.
Taking into account the stock’s recent high, it has increased by almost 49% so far this year.
